The future of topical vaccines

Episode Summary

Executive Summary: Russ Altman marks The Future of Everything’s 300th episode and features Stanford bioengineer Michael Fischbach on a possible future where vaccines are delivered as creams via skin-colonizing bacteria instead of needles. The conversation centers on surprising mouse and human findings showing skin microbes can drive strong, durable immune responses, and on the promise, safety, and next steps for translating this platform to monkeys and humans.

Main Topics: Podcast milestone and mission (Priority: 3/5): Altman frames the show’s 300th episode as a celebration and revisits the podcast’s original goal: translating Stanford research on science, engineering, medicine, and innovation into accessible stories about how people are building a better future. Discovery of immune responses to skin bacteria (Priority: 5/5): Fischbach explains that friendly skin colonists such as Staph epidermidis unexpectedly trigger large adaptive immune responses, with T cells and antibodies appearing without obvious inflammation, challenging assumptions about immune tolerance at body surfaces. Engineering bacteria as vaccine carriers (Priority: 5/5): Researchers in Fischbach’s lab genetically engineered S. epidermidis to display tumor antigens and later tetanus fragments, showing that colonizing mice with these bacteria could generate targeted immune responses against tumors and toxins. Evidence from mice and humans (Priority: 4/5): Mouse experiments showed dramatic tumor regression and strong, persistent antibody responses; human blood-bank samples also contained high antibody levels against S. epidermidis, suggesting the phenomenon may extend beyond mice. Advantages of cream-based vaccination (Priority: 5/5): The team argues that topical vaccines could eliminate needles, reduce reactogenicity, improve access without healthcare workers, induce mucosal immunity, and enable multiplexed delivery of several vaccines on different skin sites. Translation, safety, and commercialization (Priority: 4/5): The discussion covers planned monkey studies, choice of non-genetically engineered attachment methods for early human trials, exclusion of immunocompromised participants at first, and Stanford’s role in early proof-of-concept before industry scaling.

Key Arguments: Friendly skin bacteria may not be immunologically ignored; instead, they can provoke strong systemic adaptive immunity without the redness and swelling typical of injected vaccines. By decorating commensal skin bacteria with foreign antigens, scientists can redirect the immune response to fight tumors or generate protective antibodies against pathogens. The mouse data suggest the immune response is durable, systemic, and potentially more potent than some conventional vaccines, since antibody levels rose for weeks and persisted for months. Human samples showing high antibodies against S. epidermidis make the platform more plausible for people, though direct human colonization studies are still needed. Topical, needle-free vaccines could be easier to self-administer, avoid the need for a healthcare worker, reduce side effects, and be more acceptable for mass vaccination. If successful, the platform could support a unified vaccine scaffold across diseases, simplifying responses to future infectious threats.

Data Points: Podcast episode milestone: 300th episode - Altman highlights the show’s upcoming 300th episode and special guest. Mouse antibody response duration: Up to 6 weeks to peak - Antibody levels against engineered antigens rose steadily after skin colonization and topped out around six weeks. Mouse antibody persistence: 9 months - A later experiment showed antibody levels remained the same nine months after colonization. Human samples tested: 10 blood samples - Stanford blood bank samples were tested for antibodies against S. epidermidis strains. Tumor-antigen skin challenge: Head swab with Q-tip - Mice were colonized by rubbing bacteria on the head; tumors were located elsewhere in the body. Tetanus antigen size in carrier protein: 1,400 amino acids - Fischbach described the difficulty of inserting a fragment into the large surface protein AAP. Relative antibody level against tetanus: ~100-fold above protective threshold - Engineered bacteria induced tetanus antibodies far beyond the level needed to protect against lethal toxin challenge.

Pivotal Quotes: "If vaccines were to arrive in your mailbox in a catch-up packet and they didn't make you feel bad, then the way we would use them would change substantially." — Michael Fischbach: Rapid-fire closing summary of the platform’s biggest potential advantage. "We found that they left the skin, went through the bloodstream, entered the tumor, and killed tumor cells." — Michael Fischbach: Description of the surprising mouse experiment showing systemic anti-tumor immunity after skin colonization. "I think it would have four characteristics that set it apart from the vaccines you and I are used to. The first is that there would be no needle." — Michael Fischbach: Explanation of the practical benefits of a cream-based vaccine platform.

Implications: If validated in monkeys and humans, skin-applied bacterial vaccines could reshape immunization by making vaccines needle-free, potentially stronger at mucosal protection, and easier to deploy at scale. The work also hints that commensal microbes may be a programmable vaccine platform.